JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Начало・Списък с акции・Pulmatrix Inc

Pulmatrix Inc

Отворен

1.22 -0.81

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.21

Максимум

1.26

Ключови измерители
By Trading Economics
Приходи	-51K -928K
EPS	-0.254
Служители	2
EBITDA	-51K -928K

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-6.5M 4.9M
Предишно отваряне	2.03
Предишно затваряне	1.22

Pulmatrix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2026 г., 23:53 ч. UTC

Печалби

Naver Posts Weaker First-Quarter Earnings

29.04.2026 г., 23:41 ч. UTC

Горещи акции

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29.04.2026 г., 23:55 ч. UTC

Печалби

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29.04.2026 г., 23:54 ч. UTC

Печалби

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29.04.2026 г., 23:52 ч. UTC

Печалби

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29.04.2026 г., 23:51 ч. UTC

Печалби

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29.04.2026 г., 23:22 ч. UTC

Печалби

China Longyuan 1Q Net CNY1.70B, Down 14%

29.04.2026 г., 23:22 ч. UTC

Печалби

China Longyuan: Power Generation Down 2.9% as of End-March

29.04.2026 г., 23:20 ч. UTC

Печалби

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29.04.2026 г., 23:20 ч. UTC

Печалби

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke 1Q Loss Narrows>000002.SZ

29.04.2026 г., 23:18 ч. UTC

Печалби

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29.04.2026 г., 23:17 ч. UTC

Печалби

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29.04.2026 г., 23:15 ч. UTC

Печалби

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29.04.2026 г., 23:15 ч. UTC

Печалби

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29.04.2026 г., 23:13 ч. UTC

Печалби

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29.04.2026 г., 23:12 ч. UTC

Печалби

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29.04.2026 г., 23:11 ч. UTC

Печалби

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29.04.2026 г., 23:11 ч. UTC

Печалби

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29.04.2026 г., 23:04 ч. UTC

Печалби

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29.04.2026 г., 23:04 ч. UTC

Печалби

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Сравнение с други в отрасъла

Ценова промяна

Pulmatrix Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Pulmatrix Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.